JP2016538840A5 - - Google Patents

Download PDF

Info

Publication number
JP2016538840A5
JP2016538840A5 JP2016526026A JP2016526026A JP2016538840A5 JP 2016538840 A5 JP2016538840 A5 JP 2016538840A5 JP 2016526026 A JP2016526026 A JP 2016526026A JP 2016526026 A JP2016526026 A JP 2016526026A JP 2016538840 A5 JP2016538840 A5 JP 2016538840A5
Authority
JP
Japan
Prior art keywords
rhaga
protein
column
pccs2
mccs1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016526026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016538840A (ja
JP6837334B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/061789 external-priority patent/WO2015061464A2/en
Publication of JP2016538840A publication Critical patent/JP2016538840A/ja
Publication of JP2016538840A5 publication Critical patent/JP2016538840A5/ja
Priority to JP2020005541A priority Critical patent/JP7296327B2/ja
Application granted granted Critical
Publication of JP6837334B2 publication Critical patent/JP6837334B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016526026A 2013-10-23 2014-10-22 組み換え糖タンパク質及びその使用 Active JP6837334B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020005541A JP7296327B2 (ja) 2013-10-23 2020-01-17 組み換え糖タンパク質及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361894879P 2013-10-23 2013-10-23
US61/894,879 2013-10-23
US201361901942P 2013-11-08 2013-11-08
US61/901,942 2013-11-08
PCT/US2014/061789 WO2015061464A2 (en) 2013-10-23 2014-10-22 Recombinant glycoproteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020005541A Division JP7296327B2 (ja) 2013-10-23 2020-01-17 組み換え糖タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2016538840A JP2016538840A (ja) 2016-12-15
JP2016538840A5 true JP2016538840A5 (https=) 2017-11-30
JP6837334B2 JP6837334B2 (ja) 2021-03-03

Family

ID=51871299

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016526026A Active JP6837334B2 (ja) 2013-10-23 2014-10-22 組み換え糖タンパク質及びその使用
JP2020005541A Active JP7296327B2 (ja) 2013-10-23 2020-01-17 組み換え糖タンパク質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020005541A Active JP7296327B2 (ja) 2013-10-23 2020-01-17 組み換え糖タンパク質及びその使用

Country Status (33)

Country Link
US (2) US11208644B2 (https=)
EP (2) EP3060660B1 (https=)
JP (2) JP6837334B2 (https=)
KR (2) KR102479886B1 (https=)
CN (3) CN105916984A (https=)
AU (2) AU2014340152A1 (https=)
BR (1) BR112016008086A2 (https=)
CA (1) CA2927852A1 (https=)
CL (1) CL2016000961A1 (https=)
CR (1) CR20160225A (https=)
DK (1) DK3060660T3 (https=)
DO (1) DOP2016000079A (https=)
EA (1) EA034515B1 (https=)
ES (1) ES2882562T3 (https=)
HR (1) HRP20211197T1 (https=)
HU (1) HUE055236T2 (https=)
IL (2) IL245255B (https=)
LT (1) LT3060660T (https=)
MX (1) MX392532B (https=)
MY (2) MY197247A (https=)
NZ (1) NZ720384A (https=)
PE (1) PE20160723A1 (https=)
PH (1) PH12016500708B1 (https=)
PL (1) PL3060660T3 (https=)
PT (1) PT3060660T (https=)
RS (1) RS62171B1 (https=)
SG (2) SG10201803366PA (https=)
SI (1) SI3060660T1 (https=)
TN (1) TN2016000140A1 (https=)
TW (3) TWI793159B (https=)
UA (1) UA119857C2 (https=)
UY (1) UY35794A (https=)
WO (1) WO2015061464A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2017201328A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE
KR102712926B1 (ko) 2016-10-20 2024-10-07 상가모 테라퓨틱스, 인코포레이티드 파브리병의 치료를 위한 방법 및 조성물
US11357834B2 (en) 2017-01-10 2022-06-14 Amicus Therapeutics, Inc. Recombinant α-galactosidase A for treatment of Fabry disease
WO2025092951A1 (en) * 2023-11-03 2025-05-08 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant adeno-associated viral vectors for treating fabry disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
MX340738B (es) 1996-09-13 2016-07-22 Shire Human Genetic Therapies Terapia para deficiencia de a-galactosidasa a.
IL135578A0 (en) 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
US20020081654A1 (en) * 2000-04-07 2002-06-27 Sandrin Mauro Sergio Targeting hydrolase enzymes
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7133354B2 (en) 2002-08-26 2006-11-07 Qualcomm Incorporated Synchronization techniques for a wireless system
MXPA05006522A (es) * 2002-12-23 2006-02-17 Bristol Myers Squibb Co Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
CN100522988C (zh) * 2003-04-09 2009-08-05 诺和诺德公司 糖peg化方法及由该方法生产的蛋白质/肽
CA2887752C (en) * 2007-04-03 2020-03-24 Vib Vzw Glycosylation of molecules
AU2008291358A1 (en) * 2007-08-31 2009-03-05 F. Hoffmann-La Roche Ag Glycosylation profile analysis
AU2010240569A1 (en) * 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
SI2865751T1 (sl) * 2010-03-02 2017-01-31 Protalix Ltd. Stabilizirana alfa-galaktozidaza in njene uporabe
US20120178105A1 (en) 2011-01-10 2012-07-12 Genzyme Corporation Detection of globotriaosylceramide (glc) in human urine samples using an antibody sandwich
KR101883803B1 (ko) * 2011-01-20 2018-07-31 프로탈릭스 리미티드 식물 및 식물 세포에서 알파-갈락토시다제의 발현용 핵산 작제물
SG10201510106PA (en) * 2011-10-12 2016-01-28 Synageva Biopharma Corp Recombinant human naglu protein and uses thereof
EP2620506A1 (en) 2012-01-25 2013-07-31 Arla Foods Amba Method of producing a galacto-oligosaccharide-containing composition
TWI528785B (zh) 2013-02-08 2016-04-01 瑞昱半導體股份有限公司 立體影像的調整裝置及其方法
AU2014226126B2 (en) 2013-03-08 2019-02-14 Genzyme Corporation Continuous purification of therapeutic proteins

Similar Documents

Publication Publication Date Title
JP2016538840A5 (https=)
Wallach et al. Advances in the treatment of neuromyelitis optica spectrum disorder
JP2013231081A5 (https=)
GB0102687D0 (en) Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
EP4632075A3 (en) Method for reducing immunogenicity of rna
JP2012041356A5 (https=)
PL368440A1 (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
Gane et al. Phase 1a safety and pharmacokinetics of NVR 3-778, a potential first-in-class HBV core inhibitor: LB-19
JP2016530323A5 (https=)
PL368347A1 (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2006102596A3 (en) Dosage regimen for the treatment of a traumatic brain injury with progesterone
EA200800881A1 (ru) Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами
JP2011528895A5 (https=)
JP2012236857A5 (https=)
MY204380A (en) Nonracemic mixtures and uses thereof
Nishikawa et al. Coadministration of domperidone increases plasma levodopa concentration in patients with Parkinson disease
FI3581199T3 (fi) Menetelmiä turvottavan fibroskleroottisen pannikulopatian hoitamiseksi tai vähentämiseksi
JP2017537927A5 (https=)
WO2016109823A8 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
WO2007078895A3 (en) Modified release formulations of tramadol and uses thereof
Scheerens et al. Treatment with MEMP1972A, an anti-M1 prime monoclonal antibody, reduced serum IgE in healthy volunteers and patients with allergic rhinitis
KR20240132521A (ko) 항-tnf-알파 폴리펩티드 조성물 및 그 용도
ES2184561A1 (es) Forma farmaceutica solida de administracion oral dispersable en agua para el tratamiento de la tuberculosis conteniendo refampicina, isoniazida, pirazinamida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
RU2011127055A (ru) Лекарственное средство для лечения неврологическо-поведенческих расстройств развития и способ лечения неврологическо-поведенческих расстройств развития
JP2018501247A5 (https=)